ONMD$1.02
$1.01
Chart
Performance
Key Stats
AI ONMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralOneMedNet Corporation operates in the healthcare software sector, focusing on digital medical image management. The company is experiencing significant revenue and net income declines, with negative margins. While its market cap is relatively small, its enterprise value suggests a substantial debt burden relative to its current financial performance. The current stock price and its performance metrics indicate a strong downward trend, with technical indicators showing mixed signals but leaning towards bearish sentiment over longer timeframes. The company's thematic relevance is tied to healthcare IT and data management, but its current financial health raises significant concerns.
Thematic
OneMedNet is positioned within the healthcare IT sector, specifically in digital medical image management and exchange. While the broader trend towards digitalization in healthcare and the use of AI in medical imaging are positive, the company's specific financial performance and market execution are currently weak. Regulatory compliance in healthcare can also be a complex factor.
Fundamental
OneMedNet's financial fundamentals are concerning, characterized by declining revenues, substantial net losses, and negative profit margins. The company has a high debt-to-equity ratio and its cash flow generation is negative. The current valuation metrics (P/S) are exceptionally high given the minimal revenue, indicating a significant disconnect between market capitalization and its current financial output.
Technical
OneMedNet's stock has experienced a significant decline, with its current price well below its 52-week range. Technical indicators suggest a bearish trend, with most moving averages indicating sell signals on shorter timeframes, though some longer-term indicators remain mixed. The stock is trading near its 52-week low, indicating potential further downside.
| Factor | Score |
|---|---|
| Digital Health Transformation | 60 |
| AI in Healthcare Imaging | 70 |
| Data Security & Privacy (HIPAA, GDPR) | 50 |
| Market Adoption of iRWD and BEAM | 30 |
| Competition in Healthcare IT | 40 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 5 |
| Balance Sheet Health | 15 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 55 |
| Short-Term Performance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strengthening Cash Position
The company's end cash position has increased from $47,000 in Q4 2023 to $172,000 in Q4 2024, indicating improved liquidity. [29]
Improving Price-to-Sales Ratio
The Price-to-Sales (PS) ratio has decreased from 428.2 in 2021 to 97.9 in 2024, suggesting the company is becoming relatively cheaper compared to its revenue. [23]
Bearish Points (8)
Significant Net Loss
The company has consistently reported substantial net losses, with a net margin of -1575.3% in Q4 2024 and -3308.5% in Q4 2023, indicating severe profitability issues. [25, 28]
Negative Gross Profit
The company has a negative Gross Profit of -$281,000 and a significant operating expense of $9,324,000, contributing to a large operating loss of -$9,605,000. [26]
Profile
OneMedNet Corporation, a healthcare software company, provides digital medical image management, exchange, and sharing solutions in the Americas, Europe, and the Middle East. The company offers iRWD, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and artificial intelligence markets markets; and BEAM, a medical imaging exchange platform between hospital/healthcare systems, imaging centers, physicians, and patients. OneMedNet Corporation is headquartered in Eden Prairie, Minnesota.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 90
Specialized in dermatology, developing topical treatments for inflammatory skin conditions, direct overlap with ONMD's dermatology focus.
Weight: 85
Significant presence in dermatology with Opzelura (JAK inhibitor) and a robust oncology pipeline, aligning with ONMD's dual focus.
Weight: 80
Major player in oncology (Opdivo) and a growing presence in immunology/dermatology (Sotyktu for psoriasis), highly relevant to ONMD's therapeutic areas.
Weight: 78
Strong R&D and commercial presence in immunology/dermatology (e.g., psoriasis, atopic dermatitis) and oncology, making it a broader but significant peer.